Get the Stockscreener App
1.57
1.88%
-0.03
After Hours:
1.58
0.01
+0.64%
Lexicon Pharmaceuticals Inc stock is traded at $1.57, with a volume of 2.44M.
It is down -1.88% in the last 24 hours and down -9.25% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
See More
Previous Close:
$1.60
Open:
$1.58
24h Volume:
2.44M
Relative Volume:
0.86
Market Cap:
$567.54M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-2.3088
EPS:
-0.68
Net Cash Flow:
$-162.37M
1W Performance:
-0.63%
1M Performance:
-9.25%
6M Performance:
-34.58%
1Y Performance:
+44.04%
1-Day Range:
$1.54
$1.625
1-Week Range:
$1.49
$1.64
52-Week Range:
$0.92
$3.73
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals Inc (LXRX) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock - Benzinga
HC Wainwright Reiterates "Buy" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress - ForexTV.com
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 68% as the stock sheds US$54m this past week - Simply Wall St
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress - The Manila Times
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress - StockTitan
Taking a look at what insiders are doing to gauge the Lexicon Pharmaceuticals Inc (LXRX)’s direction - Knox Daily
Stocks of Lexicon Pharmaceuticals Inc (LXRX) are poised to climb above their peers - SETE News
Victory Capital Management Inc. Acquires 13,972 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Great Point Partners LLC Purchases New Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Understanding LXRX’s book value per share for better investment insights - US Post News
Upward Trajectory: Lexicon Pharmaceuticals Inc (LXRX) Posts a Slidee, Closing at 1.58 - The Dwinnex
SEC Form SC 13D filed by Innovative Eyewear Inc. - Quantisnow
Should investors be concerned about LYT’s high price-to-sales ratio? - US Post News
Lilium (NASDAQ:LILM) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
King Luther Capital Management Corp Sells 20,906 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World
Innovative Eyewear, Inc. Announces Exercise of Warrants for $2.6 Million Gross Proceeds - Yahoo Finance
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Acquired by Bank of New York Mellon Corp - Defense World
Renaissance Technologies LLC Acquires 291,000 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World
First Eagle Investment Management LLC Increases Stake in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
King Luther Capital Management Corp Sells 1,201 Shares of Lam Research Co. (NASDAQ:LRCX) - Defense World
Acadian Asset Management LLC Cuts Position in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Quest Partners LLC Invests $28,000 in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
HC Wainwright Reiterates Buy Rating for LightPath Technologies (NASDAQ:LPTH) - Defense World
Archer Aviation vs Lilium: which is the better flying car stock? - Invezz
Waterloo Capital L.P. Lowers Stock Position in Lockheed Martin Co. (NYSE:LMT) - Defense World
Can you now get a good deal on Lexicon Pharmaceuticals Inc’s shares? - US Post News
34,097 Shares in LXP Industrial Trust (NYSE:LXP) Bought by Choreo LLC - Defense World
Lexicon Pharmaceuticals President and COO Jeffrey Wade to step down - The Business Journals
Lexicon Pharmaceuticals announces executive changes By Investing.com - Investing.com Australia
Quest Partners LLC Acquires 11,597 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World
Lexicon Pharmaceuticals announces executive changes - Investing.com
Lexicon Pharmaceuticals announces executive changes By Investing.com - Investing.com Canada
Get in on Lexicon Pharmaceuticals Inc’s (LXRX) buy-in window today! - SETE News
Lexicon Pharmaceuticals announces executive changes By Investing.com - Investing.com UK
Investor’s Delight: Lexicon Pharmaceuticals Inc (LXRX) Closes Strong at 1.70, Up 1.80 - The Dwinnex
LXRXLexicon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Lexicon Pharma President, Oper Chief Jeffery Wade Leaving - MarketWatch
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer - StockTitan
Lexicon Pharmaceuticals, Inc. Appoints Kristen L. Alexander as Its Principal Financial Officer - Marketscreener.com
HC Wainwright Reiterates “Buy” Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - Defense World
Lexicon's sotagliflozin shows promise in glucose control - The Pharma Letter
HC Wainwright Reiterates Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
A new trading data show Lexicon Pharmaceuticals Inc (LXRX) is showing positive returns. - SETE News
Lexicon reports diabetes drug sotagliflozin improves glucose control - Investing.com
Lexicon reports diabetes drug sotagliflozin improves glucose control By Investing.com - Investing.com Australia
Lexicon Pharma (LXRX): New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves TIR and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes - StreetInsider.com
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes - GlobeNewswire Inc.
Daily Market Movement: Lexicon Pharmaceuticals Inc (LXRX) Sees a -0.62 Decrease, Closing at 1.61 - The Dwinnex
What technical indicators reveal about LXRX stock - US Post News
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):